Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use

EBioMedicine

Volumn 12, Issue , 2016, Pages 105-117

  Dadhania, Vipulkumar ^a   Zhang, Miao ^a   Zhang, Li ^a   Bondaruk, Jolanta ^a   Majewski, Tadeusz ^a   Siefker Radtke, Arlene ^a   Guo, Charles C ^a   Dinney, Colin ^a   Cogdell, David E ^a   Zhang, Shizhen ^a   Lee, Sangkyou ^a   Lee, June G ^a   Weinstein, John N ^a   Baggerly, Keith ^a   McConkey, David ^a   Czerniak, Bogdan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarker; Bladder cancer

Indexed keywords

CAVEOLIN 1; COLLAGEN TYPE 6; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYTOKERATIN 18; CYTOKERATIN 20; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE P60; PROTEIN P16; PROTEIN P53; PROTEIN P63; RAB PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ELF3; TRANSCRIPTION FACTOR GATA 3; TUMOR MARKER; UNCLASSIFIED DRUG; UROPLAKIN 2; UVOMORULIN;

ARTICLE; BLADDER CANCER; CYSTECTOMY; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; META ANALYSIS (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA SEQUENCE; SURVIVAL; TISSUE MICROARRAY; UPREGULATION; AGED; CANCER STAGING; CLUSTER ANALYSIS; COHORT ANALYSIS; FEMALE; GENETICS; MALE; META ANALYSIS; METABOLISM; MIDDLE AGED; MORTALITY; MUTATION; NEOPLASMS, BASAL CELL; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CLUSTER ANALYSIS; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, BASAL CELL; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 84992650854     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.08.036     Document Type: Article

References (30)

1. Aine, M., Eriksson, P., Liedberg, F., Sjodahl, G., Hoglund, M., Biological determinants of bladder cancer gene expression subtypes. Sci. Rep., 5, 2015, 10957.
2. Cancer Genome Atlas Research N, Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507:7492 (2014), 315–322.
3. Cheng, T., Roth, B., Choi, W., Black, P.C., Dinney, C., McConkey, D.J., Fibroblast growth factor receptors-1 and -3 play distinct roles in the regulation of bladder cancer growth and metastasis: implications for therapeutic targeting. PLoS One, 8(2), 2013, e57284.
4. Choi, W., Czerniak, B., Ochoa, A., et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat. Rev. Urol. 11:7 (2014), 400–410.
5. Choi, W., Porten, S., Kim, S., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:2 (2014), 152–165.
6. Czerniak, B., Dinney, C., McConkey, D., Origins of bladder cancer. Annu. Rev. Pathol. 11 (2016), 149–174.
7. Damrauer, J.S., Hoadley, K.A., Chism, D.D., et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl. Acad. Sci. U. S. A. 111:8 (2014), 3110–3115.
8. Dyrskjot, L., Thykjaer, T., Kruhoffer, M., et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet. 33:1 (2003), 90–96.
9. Groenendijk, F.H., de Jong, J., van de Putte EE, F., et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur. Urol. 69:3 (2016), 384–388.
10. Gui, Y., Guo, G., Huang, Y., et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat. Genet. 43:9 (2011), 875–878.
11. Guo, C.C., Dadhania, V., Zhang, L., et al. Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer. Eur. Urol., 2016 (March 15).
12. Kim, J.H., Tuziak, T., Hu, L., et al. Alterations in transcription clusters underlie development of bladder cancer along papillary and nonpapillary pathways. Lab. Investig. 85:4 (2005), 532–549.
13. Lawrence, M.S., Stojanov, P., Polak, P., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:7457 (2013), 214–218.
14. Lindgren, D., Frigyesi, A., Gudjonsson, S., et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 70:9 (2010), 3463–3472.
15. McConkey, D.J., Choi, W., Dinney, C.P., Genetic subtypes of invasive bladder cancer. Curr. Opin. Urol. 25:5 (2015), 449–458.
16. Moch, H., Humphrey, P., Ulbright, T., Reuter, V., WHO, Classification of Tumours of the Urinary System and Male Genital Organs. 4th ed., 2016, International Agency for Research on Cancer, Lyon.
17. Perou, C.M., Sorlie, T., Eisen, M.B., et al. Molecular portraits of human breast tumours. Nature 406:6797 (2000), 747–752.
18. Prat, A., Parker, J.S., Karginova, O., et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res., 12(5), 2010, R68.
19. Puzio-Kuter, A.M., Castillo-Martin, M., Kinkade, C.W., et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 23:6 (2009), 675–680.
20. Rosenberg, J.E., Hoffman-Censits, J., Powles, T., et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:10031 (2016), 1909–1920.
21. Shin, K., Lim, A., Odegaard, J.I., et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat. Cell Biol. 16:5 (2014), 469–478.
22. Shin, K., Lim, A., Zhao, C., et al. Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell 26:4 (2014), 521–533.
23. Singh, R.R., Murugan, P., Patel, L.R., et al. Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy. Mod. Pathol. 28:9 (2015), 1225–1235.
24. Sjodahl, G., Lauss, M., Lovgren, K., et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18:12 (2012), 3377–3386.
25. Sobin, L., Gospodarowicz, M., Wittekind, C., TNM Classification of Malignant Tumours. 7th ed., 2009, Wiley-Blackwell, Hoboken.
26. Subramanian, A., Tamayo, P., Mootha, V.K., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U. S. A. 102:43 (2005), 15545–15550.
27. Takata, R., Katagiri, T., Kanehira, M., et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin. Cancer Res. 11:7 (2005), 2625–2636.
28. Van Allen, E.M., Mouw, K.W., Kim, P., et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4:10 (2014), 1140–1153.
29. Van Batavia, J., Yamany, T., Molotkov, A., et al. Bladder cancers arise from distinct urothelial sub-populations. Nat. Cell Biol. 16:10 (2014), 982–991 (1–5).
30. Wang, H., Wang, H., Zhang, W., Fuller, G.N., Tissue microarrays: applications in neuropathology research, diagnosis, and education. Brain Pathol. 12:1 (2002), 95–107.